# US 2019/0317105 A1 · Method of Identifying Transmembrane Protein-interacting Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317105 A1
- Document ID: US20190317105A1
- Status: Published application
- Kind: A1
- Application number: 16/224,656
- Filed: 2018-12-18
- Published: 2019-10-17
- Earliest claimed: 2002-04-12
- Assignees: Omeros Corporation
- Applicants: Omeros Corporation
- Inventors: Brian F. O'Dowd; Susan R. George
- Web page: https://patentgrep.com/patent/US20190317105A1

## CPC

- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/723: {G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5035: {on sub-cellular localization}
- G01N 33/5044: {involving specific cell types}
- G01N 33/5058: {Neurological cells}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- G01N 2333/71: for growth factors; for growth regulators
- G01N 2333/72: for hormones
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G01N 2458/00: Labels used in chemical analysis of biological material
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.

## Claims

### Claim 1

A method for screening a candidate compound for its ability to interact with at least one transmembrane protein comprising:
(a) contacting a eurkaryotic cell with a candidate compound, wherein the eukaryotic cell comprises at least one nucleotide sequence encoding a protein comprising a transmembrane protein modified to alter trafficking of the ligand-bound transmembrane protein to the cell membrane and a detectable moiety, and the encoded protein is expressed in the cell; and
(b) determining the distribution of the expressed protein in the eukaryotic cell by detecting the distribution of the detectable moiety in the cell; wherein detection of an altered distribution of the detectable moiety in the cell relative to the distribution of the detectable moiety in a control cell not contacted with the candidate compound indicates that the compound interacts with the transmembrane protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the transmembrane protein is modified to facilitate ligand-independent trafficking of the transmembrane protein away from the cell membrane.

### Claim 3 (depends on 2)

The method of claim 2, wherein the transmembrane protein is modified to contain an amino acid sequence that facilitates ligand-independent trafficking of the transmembrane protein away from the cell membrane.

### Claim 4 (depends on 1)

The method of claim 1, wherein the eukaryotic cell is selected from the group consisting of a mammalian cell, a yeast cell, an insect cell, a nematode cell, a plant cell and a fungal cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the detectable moiety is a detectable peptide comprising an antigenic portion of the amino acid sequence of the transmembrane protein.

### Claim 6 (depends on 5)

The method of claim 5, wherein the detectable moiety is an antigenic peptide and the distribution of the antigenic peptide in the cell is determined by allowing it to bind to an antibody-based detection system comprising an antibody specific for the antigenic peptide.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody-based detection system comprises a first antibody specific for the antigenic peptide and a second antibody carrying a detectable label and specific for the first antibody.

### Claim 8 (depends on 6)

The method of claim 6, wherein the antibody-based detection system comprises a first antibody specific for the antigenic peptide comprising a detectable label.

### Claim 9 (depends on 1)

The method of claim 1, wherein the detectable moiety is at least one of an optically detectable label, a luminescent label, or a fluorescent label.

### Claim 10 (depends on 1)

The method of claim 1, wherein the detectable moiety is an enzyme which can be reacted to give a detectable end point.

### Claim 11 (depends on 10)

The method of claim 10, wherein the enzyme is β-galactosidase.

### Claim 12 (depends on 1)

The method of claim 1, wherein the detectable moiety is a polypeptide selected from the group consisting of green fluorescent protein, red fluorescent protein and modified variants thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the transmembrane protein is selected from the group consisting of a G protein-coupled receptor (GPCR), a transporter, a cytokine receptor, a tyrosine kinase receptor and a low-density lipoprotein (LDL) receptor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the transmembrane protein is a GPCR.

### Claim 15 (depends on 14)

The method of claim 14, wherein the GPCR is selected from the group consisting of a dopamine D1 receptor, a dopamine D2 receptor, a dopamine D3 receptor, a dopamine D5 receptor, a histamine 1 receptor, a cysteinyl leukotriene receptor 1, a cysteinyl leukotriene receptor 2, an opioid receptor, a muscarinic receptor, a serotonin receptor, a beta2-adrenergic receptor and a metabotropic glutamate 4 receptor.

### Claim 16 (depends on 3)

The method of claim 3, wherein the nucleotide sequence encoding the transmembrane protein is modified within a region encoding an intracellular domain of the protein to contain an amino acid sequence that facilitates ligand-independent transfer of the transmembrane protein away from the cell membrane.

### Claim 17 (depends on 3)

The method of claim 3, wherein the nucleotide sequence encoding the transmembrane protein is modified within a region encoding the proximal carboxyl tail to contain an amino acid sequence that facilitates ligand-independent transfer of the transmembrane protein away from the cell membrane.

### Claim 18 (depends on 3)

The method of claim 3, wherein the nucleotide sequence encoding the transmembrane protein is modified within a region encoding helix 8 to contain an amino acid sequence that facilitates ligand-independent transfer of the transmembrane protein away from the cell membrane.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cell is contacted with a compound known to interact with the at least one transmembrane protein prior to contacting the cell with the candidate compound and wherein detection of an altered distribution of the detectable moiety in the cell relative to the distribution of the detectable moiety in a control cell contacted with the compound known to interact with the transmembrane protein but not contacted with the candidate compound indicates that the candidate compound interacts with the transmembrane protein.
